Use of Microdilution Panels with and Without Beta-lactamase Inhibitors As a Phenotypic Test for Beta-lactamase Production Among Escherichia Coli, Klebsiella Spp., Enterobacter Spp., Citrobacter Freundii, and Serratia Marcescens
Overview
Authors
Affiliations
Over the past decade, a number of new beta-lactamases have appeared in clinical isolates of Enterobacteriaceae that, unlike their predecessors, do not confer beta-lactam resistance that is readily detected in routine antibiotic susceptibility tests. Because optimal methodologies are needed to detect these important new beta-lactamases, a study was designed to evaluate the ability of a panel of various beta-lactam antibiotics tested alone and in combination with beta-lactamase inhibitors to discriminate between the production of extended-spectrum beta-lactamases, AmpC beta-lactamases, high levels of K1 beta-lactamase, and other beta-lactamases in 141 isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, and Serratia marcescens possessing well-characterized beta-lactamases. The microdilution panels studied contained aztreonam, cefpodoxime, ceftazidime, cefotaxime, and ceftriaxone, with and without 1, 2, and 4 microg of clavulanate per ml or 8 microg of sulbactam per ml and cefoxitin and cefotetan with and without 8 microg of sulbactam per ml. The results indicated that a minimum panel of five tests would provide maximum separation of extended-spectrum beta-lactamase high AmpC, high K1, and other beta-lactamase production in Enterobacteriaceae. These included cefpodoxime, cefpodoxime plus 4 microg of clavulanate per ml, ceftazidime, ceftriaxone, and ceftriaxone plus 8 microg of sulbactam per ml. Ceftriaxone plus 2 microg of clavulanate per ml could be substituted for cefpodoxime plus 4 microg of clavulanate per ml without altering the accuracy of the tests. This study indicated that tests with key beta-lactam drugs, alone and in combination with beta-lactamase inhibitors, could provide a convenient approach to the detection of a variety of beta-lactamases in members of the family Enterobacteriaceae.
Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam.
Kaur J, Mahajan G, Chand K, Sheevani , Chopra S J Clin Diagn Res. 2016; 10(1):DC05-8.
PMID: 26894064 PMC: 4740591. DOI: 10.7860/JCDR/2016/15264.7041.
AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India.
Gupta V, Kumarasamy K, Gulati N, Garg R, Krishnan P, Chander J Indian J Med Res. 2012; 136(2):237-41.
PMID: 22960890 PMC: 3461735.
Ahmed S, Daef E, Badary M, Mahmoud M, Abd-Elsayed A BMC Res Notes. 2009; 2:76.
PMID: 19419535 PMC: 2694819. DOI: 10.1186/1756-0500-2-76.
Thomson K, Cornish N, Hong S, Hemrick K, Herdt C, Moland E J Clin Microbiol. 2007; 45(8):2380-4.
PMID: 17596369 PMC: 1951213. DOI: 10.1128/JCM.00776-07.
Moland E, Hanson N, Black J, Hossain A, Song W, Thomson K J Clin Microbiol. 2006; 44(9):3318-24.
PMID: 16954267 PMC: 1594717. DOI: 10.1128/JCM.00756-06.